Aiming to brush last year's flop aside, Fulcrum sees shares skyrocket on early look at sickle cell program

Fulcrum Therapeutics $FULC is looking to rebound after the Phase II flop of an old GlaxoSmithKline drug slashed their market value in half last August. And if Tuesday’s stock movement is any indication, investors like what they see.